Clinical trial NCT01933919: A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
Official title: A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Obsessive Compulsive Disorder
Keywords: Obsessive Compulsive Disorder
Adolescent Subjects
Pediatric Subjects
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
Collaborators: name: Meiji Seika Pharma Co., Ltd.
First posted: 2013-09-02
Enrollment: 38
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10 weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD).

The objective of the second phase of the study is to evaluate the long-term safety and efficacy of fluvoxamine in pediatric/adolescent patients with OCD.

Detailed description: The first phase will be conducted in a randomized, placebo-controlled, double-blind manner to evaluate the efficacy of fluvoxamine on change from baseline to the last observation visit in the JCY-BOCS 10-item total score. Eligible patients will be allocated to the fluvoxamine group or placebo group in a 1:1 ratio using the experience of fluvoxamine treatment and age as stratification factors (dynamic allocation). The first phase consists of a screening period of 1-2 weeks, a forced titration dose period of 2 weeks, a dose adjustment period of 4 weeks, a maintained dose period of 4 weeks, and a tapering dose period of 0-4 weeks.

The 2nd phase will be conducted in an open-label manner in participants who completed the first phase to evaluate the long-term safety of fluvoxamine. The 2nd phase consists of 3 periods; a forced titration dose period of 2 weeks, a flexible dose period of 50 weeks, and a tapering dose period of 0-4 weeks. After the last dose of study drug (including tapering dose period) or the early termination visit, participants will be followed for up to 30 days.

Eligibility criteria: Inclusion Criteria:

1. Subject has at least 16 points on Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score and at least 5 points in Obsession sub-total score and in Compulsion sub-total score respectively at the Screening period and Baseline.
2. Subject showed less than 25% reduction in Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score at Baseline compared to the score at the Screening period (Total score at Baseline ≥ Total score at Screening х 0.75).
3. Subject has obsessive compulsive disorder symptoms at least for 2 months at informed consent.
4. Body weight: ≥ standard weight - 2 standard deviation based on the standard weight for each age in the School Health Statistical Survey 2001.
5. Subjects with parent or legal guardian who have received explanation about the purpose, procedure and meaning of the study sufficiently and is willing to give written informed consent for the subject. (if possible, written informed assent will be obtained from the subject).

Exclusion Criteria:

1. Subject has only trichotillomania (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 312.39) or nail-biting as his/her compulsive symptoms.
2. Subject has Tourette's disorder (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 307.23). However, the simple motor tic is not excluded.
3. Subject is diagnosed with the following psychiatric disorders.

   * Schizophrenia (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 295.xx) and other psychotic disorders (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 295.40 \[schizophreniform disorder\], 295.70 \[schizoaffective disorder\], 297.1 \[delusional disorder\], 298.8 \[brief psychotic disorder\], 297.3 \[shared psychotic disorder\], 293.xx \[psychotic disorder due to... {indicate the general medical condition}\], substance induced psychotic disorder, 298.9 \[psychotic disorder not otherwise specified\]).
   * Depressive disorders Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 296.xx \[major depressive disorder\], 296.2x \[single episode\], 296.3x \[recurrent\], 300.4 \[dysthymic disorder\], 311 \[depressive disorder not otherwise specified\]).
   * Bipolar disorders (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 296.xx \[bipolar I disorder\], 296.0x \[single manic episode\], 296.40 \[most recent episode hypomanic\], 296.4x \[most recent episode manic\], 296.6x \[most recent episode mixed\], 296.5x \[most recent episode depressed\], 296.7 \[most recent episode unspecified\], 296.89 \[bipolar II disorder\], 301.13 \[cyclothymic disorder\], 296.80 \[bipolar disorder not otherwise specified\]).
   * Mental retardation (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 317 \[mild mental retardation\], 318.0 \[moderate mental retardation\], 318.1 \[severe mental retardation\], 318.2 \[profound mental retardation\], 319 \[mental retardation, severity unspecified\]).
   * Eating disorders (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 307.1 \[anorexia nervosa\], 307.51 \[bulimia nervosa\], 307.50 \[eating disorder not otherwise specified\]).
   * Attention-deficit/hyperactivity disorder (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 314.xx) and attention deficit/hyperactivity disorder not otherwise specified (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 314.9).
   * Obsessive compulsive personality disorder (Diagnostic and Statistical manual of Mental Disorders Forth Edition Text Revision: 301.4).
   * Other patients with clinical neurological disorder.
4. Subject who diagnose Major Depressive Disorder by The Mini-International Neuropsychiatric Interview for Children and Adolescents (A) at the Screening period.
5. Subject has been treated with fluvoxamine within 2 months prior to informed consent. Except for the patient whose fluvoxamine dose is not fixed and the administration period of fluvoxamine is within 6 weeks.

Primary outcomes:
measure: Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase
timeFrame: Baseline and week 10
Secondary outcomes:
measure: Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Age
timeFrame: Baseline and week 10
measure: Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Gender
timeFrame: Baseline and week 10
measure: Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the First Phase
timeFrame: Baseline and weeks 2, 4, 6, 8 and 10
measure: JCY-BOCS 10-item Total Score at Each Visit During the First Phase
timeFrame: Baseline and weeks 2, 4, 6, 8 and 10
measure: Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the First Phase
timeFrame: Weeks 1, 2, 3, 4, 5, 6, 8, and 10
measure: Percentage of Participants With a ≥ 25% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase
timeFrame: Baseline and week 10
measure: Percentage of Participants With a ≥ 35% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase
timeFrame: Baseline and week 10
measure: Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the Second Phase
timeFrame: Baseline of the 2nd phase and weeks 2, 8, 16, 28, 40, and 52 of the 2nd phase
measure: Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the Second Phase
timeFrame: Baseline of the 2nd phase and weeks 1, 2, 3, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
measure: Number of Participants With Adverse Events During the First Phase
timeFrame: From the first dose of the study drug up to 30 days after the last dose of the study drug, approximately 18 weeks in the first phase.
measure: Number of Participants With Adverse Events During the Second Phase
timeFrame: From the first dose of the study drug up to 30 days after the last dose of the study drug, approximately 60 weeks in the second phase of the study.
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: Susumu Matsuki, BS
role: STUDY_DIRECTOR
References: